Guest guest Posted April 18, 2004 Report Share Posted April 18, 2004 LDN Website Update April 2004 www.low dose naltrexone.org / www.ldninfo.org 1) Latest News for April 2004 has been posted on the website, as follows: Increasing Attention to LDN for MS: * On April 12, 2004 The Herald, the venerable newspaper of Glasgow, Scotland, carried a feature article and an editorial concerning the increasing number of people who are petitioning for holding clinical trials specifically among people with MS in order that LDN could be licensed for their use. This marks the first attention we are aware of to LDN in the public press. * A petition on the Internet, which was mounted in the UK in order to gather support for a clinical trial of LDN in MS, already had over 3000 signatures by mid-April. * A survey of those with MS who are taking LDN, covering a host of issues and individual comments, had gathered over 200 responses as of this writing. To see all the responses, go to the website, select " 300 " and press " Submit Query " . [see http://www.low dose naltrexone.org/ldn_latest_news.htm for hyperlinks to visit the above-mentioned websites.] 2) Search Feature. A new search feature has been added to the LDN website, and can be found at the top of the homepage, and at the bottom of every page of the site. To use, type in text to search for, and press enter or click the blue 'Search' button. A search engine (Google) will provide a list of pages on this website containing your search text — click on a search result to go to that page. To locate your search text on that page, use the 'Find' feature of your browser (usually accessible by typing Ctrl+F). 3) Other updates include the addition of Primary Lateral Sclerosis (PLS) to the list of diseases on the homepage. LDN Website Editors email@... Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.